Association Between Matrix Metalloproteinase-2 Gene Polymorphism rs243865 and Susceptibility to Cataract Development

NCT ID: NCT05670834

Last Updated: 2024-07-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

90 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-07-01

Study Completion Date

2024-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary aim of this study is to investigate the potential association between MMP-2 gene polymorphism and susceptibility to cataract development in Egyptian patients. Furthermore, this study aims to compare between cataract patients and healthy controls by measuring the serum IL-6 concentration to evaluate its relationship with disease.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Cataract is a leading cause of blindness worldwide and is more common in low socioeconomic states and developing countries. According to the WHO, among 3 million visually impaired and 1 million blind persons in Egypt, about 60% have cataract.

The lens undergoes several morphological, biochemical, and physical changes with age which are causal for the formation of age-related cataract.

Oxidative stress can directly influence the solubility of the lens proteins, which increases the lens's opacity.

some studies suggest that inflammatory response may be involved in the occurrence of catarac. and that the pathophysiology is largely attributed to peptide mediators, such as transforming growth factor-beta (TGF-β), epidermal growth factor (EGF) and matrix metalloproteinases (MMPs), with the inhibition of these and other related molecules showing promising results.

Matrix metalloproteinases (MMPs) are a kind of calcium-zinc ion-dependent proteolytic enzyme involved in a variety of cellular processes. MMPs are well known for their ability to degrade the extracellular matrix (ECM) and are involved in several intracellular mechanisms from cell differentiation, proliferation, and angiogenesis to apoptosis.

Several studies' results suggest that the rs243865 (16q13-q21) polymorphism in the promoter region of the metalloproteinase-2 (MMP-2) gene is associated with ophthalmological disorders such as age-related macular degeneration. A recent study suggested that the MMP-2 rs243865 (C/T) polymorphism is associated with an increased risk of cataract.

The expression and activation of MMP-2 can be regulated by environmental influences from surrounding stroma, such as cytokines. some studies suggest that IL6 upregulates the expression of MMPs including MMP-2.

IL-6 is a soluble mediator with a pleiotropic effect on inflammation, immune response, and hematopoiesis. high levels of Il-6 in cataract patients may support the inflammatory response theory of disease development.

this study will follow the tenets of the Declaration of Helsinki. All study participants will sign informed written consent before enrolment in this study.

All study participants will be subjected to complete ophthalmic examination including slit-lamp and fundus examinations. Detailed medical history will be taken.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cataract

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

control group (GroupA)

normal healthy non-cataractous volunteers aged ≥21 years

genotyping assay by real-time PCR

Intervention Type GENETIC

genotyping assay of MMP-2 gene with the real-time polymerase chain reaction

ELISA

Intervention Type DIAGNOSTIC_TEST

. IL-6 level in serum will be analyzed by ELISA assay kit.

Group B (experimental group 1)

cataractous patients aged \>50 years and diagnosed with senile cataract.

genotyping assay by real-time PCR

Intervention Type GENETIC

genotyping assay of MMP-2 gene with the real-time polymerase chain reaction

ELISA

Intervention Type DIAGNOSTIC_TEST

. IL-6 level in serum will be analyzed by ELISA assay kit.

Group C (experimental group 2)

cataractous patients aged ≥21 to 50 years and diagnosed with secondary cataract

genotyping assay by real-time PCR

Intervention Type GENETIC

genotyping assay of MMP-2 gene with the real-time polymerase chain reaction

ELISA

Intervention Type DIAGNOSTIC_TEST

. IL-6 level in serum will be analyzed by ELISA assay kit.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

genotyping assay by real-time PCR

genotyping assay of MMP-2 gene with the real-time polymerase chain reaction

Intervention Type GENETIC

ELISA

. IL-6 level in serum will be analyzed by ELISA assay kit.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Group A (control group) will include 30 eyes of 30 normal healthy non-cataractous volunteers aged ≥21 years. Group B (experimental group 1) will include 30 eyes of 30 cataractous patients aged \>50 years and diagnosed with senile cataract. Group C (experimental group 2) will include 30 eyes of 30 cataractous patients aged ≥21 to 50 years and diagnosed with secondary cataract. The control group will include participants who will be age-matched and sex-matched with the patients in the experimental groups

Exclusion Criteria

* concomitant eye pathology or inflammation, systemic diseases and previous eye or systemic surgery.
Minimum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sohag University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Tasneem Sayed Hawwary Ahmed

demonstrator

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Faculty of Medicine Sohag University

Sohag, , Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

References

Explore related publications, articles, or registry entries linked to this study.

Dong Y, Mu GY, Chen F, Zhao RL, Wang M, Wang B. Correlation between MMP-2 gene polymorphism and cataract susceptibility. Eur Rev Med Pharmacol Sci. 2019 Apr;23(8):3167-3172. doi: 10.26355/eurrev_201904_17674.

Reference Type BACKGROUND
PMID: 31081067 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Soh-Med-22-12-06

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.